ROCKVILLE, Md., April 20, 2021 /PRNewswire/ — Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that Michael Gaffney has joined the company as Chief Executive Officer, effective immediately. Mr. Gaffney brings deep health sector insight, extensive operational experience, and proven strategy and capital markets expertise to Cellphire. He will also join the Company’s board.
{iframe}https://finance.yahoo.com/news/cellphire-therapeutics-names-michael-gaffney-153200417.html{/iframe}